Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (3007)	7/11/1998 10:07:00 PM
From: Prospector	Respond to of 5402

let me see if I can read yer mind..... Dr Epstein..... mmmmmmmmmmmm Yes until the animal trails have results we don't have news...... Ok I think this being a second Generation Drug it has a pretty fair chance of just doing that... Prospector

To: chirodoc who wrote (3007)	7/19/1998 7:55:00 PM
From: Prospector	Read Replies (1) \| Respond to of 5402

Mr Chirodoc Answers to your questions as per Dr Drees 1. Flousol had slight allergic reactions in clinical trail patients, which went away when mild steroids were given to the few patients affected. The new formulation has a tighter bond in the emulsion, because the new surfactant is also fluoronated to improve emulsion stability so that he finished emulsion does not have to be frozen, as did fluosol. 2. Time table for Phase 1 (19990 , Phase 2 (2000) Phase 3 (2001). 3. The dosage will vary with the usage,i.e. angioplasty (400 ml ), transfusion (500 ml x 4) etc. 4. We will branch out to the 150 areas we know about, and more. 5. Most likely side affects of PHER-02 is a slight allergic reaction and it is not dose dependant.